Chairman's foreword

Welcome to the ADDMEDICA Internet website.

Since its foundation in 2005, ADDMEDICA has constantly developed with focus on patients suffering from rare diseases or severe clinical conditions.

  • In hematology, the company holds the European Marketing Approval of the sole drug indicated in a rare disease called Sickle Cell Disease.
  • In the domain of organ grafts, it distributed in France the best fitted preservation solution for pulmonary grafts, as well as an experimental solution designed to assess the functionality of the lung before transplantation.
  • Lastly, in the domain of wound healing, it commercializes a range of high technology products, mainly for hospital use.

Some new products are soon expected to complete this range, always oriented towards unmet medical needs.

Proud of the past accomplishments, all ADDMEDICA team, motivated by its useful mission, is entering the coming years with confidence in its success.

 

François ANGER
Chairman

Rotation-of-DSCN2206.JPG
Last update date: 27/07/2016
Last update date: 27/09/2018